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EDITORIAL
Twenty years after: the beautiful 
hypothesis and the ugly facts
Francesco Pezzella1* , Kevin Gatter1 and Chao‑Nan Qian2
Abstract 
The limited clinical benefits from current antiangiogenic therapy for cancer patients have triggered some critical 
thoughts and insightful investigations aiming to further elucidate the relationship between vessels and cancer. 
Tumors need blood perfusion but there are mounting evidences that angiogenesis alone does not explain it in all 
the neoplasms. In this editorial, for a special issue on tumor and vessels published in the Chinese Journal of Cancer, 
we briefly introduce the history of the evidences that solid tumors can sometimes obtain blood perfusion by alter‑
native approaches other than sprouting angiogenesis, i.e., vessel co‑option and vasculogenic mimicry. This editorial 
provides also the links to several most recently published discoveries and hypotheses on tumor interaction with 
blood vessels.
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“The great tragedy of science–the slaying of a beautiful 
hypothesis by an ugly fact.” Thomas Huxley.
Heraclitus of Ephesus, one of the most distinguished 
Greek thinkers, had at the core of his philosophy the 
idea that everything changes. According to Plato, “Hera-
clitus, I believe, says that all things go and nothing stays, 
and comparing existents to the flow of a river, he says 
you could not step twice into the same river” (Cratylus 
402a  =  DK22A6). Twenty years after the special issue 
on angiogenesis published in the European Journal of 
Cancer [1], we are stepping into another special issue, 
concerning the relationship between cancer and blood 
vessels, of the Chinese Journal of Cancer and things have 
certainly changed! Perhaps the first thing to be noticed is 
that this time we will not get a single bounded issue with 
all the contributions inside. We will rather end up with 
a website link leading to the collection of papers, to be 
posted throughout the next 12 months or so, on a server. 
The journal has changed as well, from the European Jour-
nal of Cancer to the Chinese Journal of Cancer, as a result 
of an ever-increasing wide but tightly connected research 
community. However, what about the subject of the two 
issues? In 1996, it was firmly about the fundamental role 
of angiogenesis, i.e., the formation of new vessels, in can-
cer but now is going to be about cancer and blood ves-
sels—not only newly formed but also pre-existing, plus 
vascular-mimicking structures.
The fundamental question behind all this is how the 
cancer cells get provided with the necessary oxygen and 
nutrients in order to stay alive and growth. The prevalent 
theory at the time of the European Journal of Cancer spe-
cial issue was the one, introduced in 1971 by Folkman [2], 
that tumor growth is strictly angiogenesis-dependent. 
However, the discovery that tumor can also grow with-
out angiogenesis, by co-opting pre-existing vessels in 
humans [3–7] and in mice [8] plus the possibility, known 
as “vascular mimicry,” for the very same neoplastic cells 
to form vessel-like structures able to provide blood per-
fusion, has demonstrated that this is not always the case 
[9]. These observations provide a new aspect of the inter-
action between vessels and tumors, shed new light on the 
biology of the latter, and have implications for resistance 
to antiangiogenic drugs and development of new target-
ing strategies. The relationship between cancer and blood 
vessels is emerging as much more complex than until 
now thought; while angiogenesis remains a fundamental 
part of it, it is clearly not the all story.
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But how new are the findings that cancer can also grow 
exploiting pre-existing vessels in complete absence of 
angiogenesis? It would be surprising that such important 
role played by the normal vessels of the body in supporting 
the spread of cancers had been so far ignored. As a mat-
ter of fact it was not ignored as the idea that cancer must 
have had a tight relationship with vasculature is an old one 
and different theories have been discussed throughout the 
time. Kolin et al. [10] described primary lung carcinomas 
“often growing mainly in air spaces and preserving the 
pulmonary framework as their stroma.” In the General 
Pathology textbook edited in 1962 by Florey [11], Ritchie 
wrote, in the chapter on “The classification, morphology, 
and behaviour of the tumors,” that “One of the principal 
functions of the stroma is to provide a blood supply within 
the tumor mass.” but “Sometime a tumor will supplement 
or replace the stroma by using pre-existing structures. For 
example occasional tumors in the lung grow round the 
alveoli using the alveolar walls in place of stroma.”
Reading backwards, in his  1934 book “The spread of 
tumors in human body” Willis [12] wrote that “Intra 
alveolar growth of tumors in the lung is a characteristic 
and frequent mode of extension” in which “the plugs of 
growth occupying the air sacs are themselves avascu-
lar, the septal walls constituting the only stroma of the 
tumors.” Willis credited for the original description of 
these tumors an article published in 1861. In that study 
entitled “Zwei falle von carcinosis acuta miliaris” (Two 
cases of acute miliary carcinomatosis), Erichsen [13] 
described how the neoplastic cells in lung tumors occupy 
the alveolar spaces but no new vessels can be seen; he 
also illustrated his point with a remarkable “Camera 
Lucida” drawing. The diverse findings from different 
investigators, which try to unravel how cancer and ves-
sels interact, have been until now looked at as somehow 
in contrast among them, but we have nowadays accepted 
that they are all in the thick of it!
The most immediate consequence of the recognition 
that malignant cells can exploit pre-existing vessels has 
been the opening of two new big fields in cancer biology.
The first is, of course, the biology of the non-angiogenic 
cancer cells: why some of them induce angiogenesis while 
others can go all the way of exploiting pre-existing vessels 
and how the biology of these two types of tumors differs. 
It is worthy noting that in many tumors both angiogenic 
and non-angiogenic areas are identified [3];
The second is the biology of vessel co-option: how can-
cer cells do it? Plus the obvious subsequent question: how 
does this affect treatment with the present day drugs, and 
can new targets be discovered?
These will be the first papers among those of our “vir-
tual” special issue papers of the Chinese Journal of Cancer. 
Dr. Qian and colleagues [14] discussed vessel remodeling 
accompanying vessel co-option as well as the different 
features between vessel-like structure and tubule-like 
structure. Dr. Paku and his team [15] reviewed the bio-
logical features of the mechanisms underlying vessel co-
option and other alternative angiogenic approaches in 
the primary and metastatic tumor lesions. Dr. Pezzella 
and his team [16] showed that hypoxia occurs in a com-
parable way in angiogenic and non-angiogenic tumors 
and proposed a hypothesis that in some, but not in all, 
cases, initial tissue remodeling and/or inflammation 
could possibly be one of the second steps, following the 
establishment of hypoxia, necessary to trigger tumor 
angiogenesis. In the non-angiogenic tumors, where neo-
vascularization fails to occur, hypoxia-inducible fac-
tor (HIF) pathway activation could be the driving force 
toward metabolic reprogramming. Dr. Luo and his group 
[17] reported that mono-PEGylated endostatin had a 
promising property on inhibiting tumor angiogenesis. Dr. 
Cao [18] discussed the possible mechanisms of various 
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